drug

diranersen

1 story · latest Jul 29, 2026

Status: Investigational
Codes: BIIB080, ISIS 814907
Trials: 2 registered trials in coverage

Relationships

Developed by Biogen

Timeline

Biogen posts Q2 2026 results, sets five late-stage readouts over next four quarters

Jul 29Quarterly updateBiogen felzartamab

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.